7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square

NEWS

November 13, 2019

ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseas...

September 30, 2019

  • ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investin...

July 25, 2019

Dr Jean Bousquet, a renowned expert in pulmonary allergy, has delivered a keynote lecture on the next generation guideli...

July 10, 2019

  • 3 million dollars invested by Medici Investment

  • European Clinical phase 2 study of JM-010 to treat dyskinesia i...

July 5, 2019

The sales of Dexid for diabetic polyneuropathy, Legalon for liver disease, and Entecavir for chronic hepatitis B are boo...

July 3, 2019

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based B...

July 1, 2019

Bukwang’s successful launch of Neomed toothpaste on home-shopping marked its expansion on OTC business.

  • A functional...

June 28, 2019

  • BNO BIO has invested $1 million in Nucleix, an Israeli bio-venture

  • The first global investment by BNO BIO since...

June 26, 2019

- to be completed within 2 years

Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM...

December 17, 2018

- Fast speed of study progression, expecting results in January next year

MLR-1023’s phase 2b study is completed on Decem...

Please reload

Recent
Please reload

|    ​Korean    |